Expression of Alpha Methyl Acyl-CoaRacemase (AMACR) Immunohistochemistry in Carcinoma Prostate in Tertiary Care Hospital

Abstract

Objective: Prostate needle biopsy samples from cancer patients at a tertiary care hospital were analysed for the presence of the potential screening indicator alpha-methylacyl-COA RACEMES. Material and Methods: This was a Cross-sectional study carried out at Department of Histopathology, Lady Reading Hospital Peshawar from June, 2021 to December, 2021.Regardless of the patient's age, tumour grade, or histological type, all adenocarcinoma prostate specimens diagnosed at the Lady Reading Hospital Peshawar on the basis of immunohistochemistry and routine histology were examined. Standard and mean deviation were computed for quantitative factors of patient like age and frequencies, percentages were calculated for qualitative factors like AMACR expressions. Results: Outof 90 cases, AMACR positivity was found in 68 (85%), while negativity was seen in 22 (15%). Nine (11.3%) of the negative cases had one staining (weak, non-circumferential) and three cases (3%) had no stainings (No cytoplasmic staining). Conclusion: Positive AMACR staining on prostate needle core necropsies may be utilised to support a cancer diagnosis when the focus at issue is 1 mm in highest diameter. Basic hematoxylin and eosin standards for malice require analysis of cell-specific markers like P63 or 34E12. AMACR labelling must be interpreted in the context of other labels that can be used to find out more. Keywords: Adenocarcinoma of the prostate, Alphamethylacyl-CoA racemase (AMACR), Immunohistochemistry.